The 2026 SOT Annual Meeting is a key forum for advancing safety science and translational toxicology. Veloxity will be attending to connect with toxicologists, program leads and development teams supporting preclinical and IND-enabling studies.

Our bioanalytical work supports toxicology programs that require reliable PK/TK data, clean handoffs and predictable timelines. We frequently partner with teams managing complex matrices, small sample volumes and accelerated study schedules — where operational discipline makes the difference.

Veloxity attendees:

• Callie Celichowski, Senior Director, Business Development
• Mitch Johnson, PhD, Co-Founder, Laboratory Director​
• Jake Taylor, Manager, Business Development

If you’ll be at SOT, reach out to discuss bioanalysis and PK/TK support for toxicology and IND-enabling studies.